Herbal Composition DCB-SLE1 for Lupus Nephritis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lupus nephritis, a severe complication of systemic lupus erythematosus, are inadequate, with significant side effects and no definitive cure, necessitating alternative therapies that can effectively manage renal inflammation and autoantibody production.
Innovation Solution
An herbal pharmaceutical composition comprising Rhizoma Atractylodis Macrocephalae, Eucommiae Cortex, Lonicerae Caulis, and Hedyotidis Diffusae Herba, known as DCB-SLE1, is administered to mitigate renal inflammation, autoantibody production, and immune complex deposition, prepared by a mixture of these herbs soaked in water, heated, filtered, and concentrated to create a hot-water extract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (corticosteroids with cytotoxic agents or immunomodulators) are used for lupus nephritis, then renal function can be normalized and proteinuria reduced, but significant side effects occur and no definitive cure is achieved
Solution Approach 1:
The patent changes the chemical composition parameters of the treatment by replacing conventional cytotoxic agents and immunomodulators with a specific herbal composition containing four traditional Chinese medicines (Rhizoma Atractylodis Macrocephalae, Eucommiae Cortex, Lonicerae Caulis, and Hedyotidis Diffusae Herba) in defined proportions, thereby maintaining therapeutic effectiveness while eliminating harmful side effects
Solution Approach 2:
The patent employs a composite herbal formulation combining four different traditional Chinese medicinal materials, each contributing specific pharmacological activities that work synergistically to treat lupus nephritis, thereby achieving comprehensive therapeutic effects without the toxicity of single-agent conventional treatments
2Adaptability or versatility
If conventional treatments are administered, then some renal function normalization occurs, but treatment protocols vary and are not specifically indicated for lupus nephritis
Solution Approach 1:
The patent develops a universal herbal formulation specifically designed for lupus nephritis that addresses multiple pathogenic mechanisms simultaneously (immune complex deposition, inflammation, renal damage), making it applicable across varying treatment scenarios without requiring protocol adjustments
3Reliability
If DCB-SLE1 herbal composition is administered, then proteinuria, hematuria, and renal function defects are reduced, but the mechanism involves suppressing T cell and NK cell activation and inhibiting inflammatory cytokines
Solution Approach 1:
The patent converts the harmful inflammatory response and immune activation into a beneficial therapeutic effect by using herbal compounds that modulate the immune system to reduce pathological inflammation while preserving protective immune functions, thereby transforming the disease mechanism against itself
Data Source
AI summary
This invention relates to methods for treatment of nephritis. This invention further provides a method of treating with nephritis comprising administering to the subject an amount of herbal pharmaceutical composition thereof effective to treat the subject. Move particularly, this invention provides an herbal pharmaceutical composition comprising Rhizoma Atractylodis macrocephalae, Eucommiae cortex, Lonicerae caulis, and Hedyotidis diffusae Herba thereof for use in treating a subject afflicted with active nephritis.